Business Context and Reporting Period
Company: CURIS, INC.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2009
Business Overview: Curis is a drug discovery and development company focused on targeted cancer therapies. Its primary revenue sources are license fees and contingent payments from strategic collaborations, specifically with Genentech (Hedgehog pathway inhibitor GDC-0449) and Debiopharm (Hsp90 inhibitor Debio 0932). The company has no commercial product sales and operates in a single segment.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 | Balance Sheet (Sep 30, 2009) |
|---|---|---|---|
| Total Revenues | $765,313 | $6,865,703 | - |
| Net Loss | $(4,060,296) | $(7,116,623) | - |
| Loss Per Share (Basic/Diluted) | $(0.06) | $(0.11) | - |
| Cash and Cash Equivalents | - | - | $6,803,801 |
| Marketable Securities | - | - | $20,411,153 |
| Total Current Assets | - | - | $27,873,960 |
| Total Current Liabilities | - | - | $3,497,069 |
| Accumulated Deficit | - | - | $(715,087,459) |
Liquidity: As of September 30, 2009, the company held approximately $27.2 million in cash, cash equivalents, and marketable securities. Management anticipates these resources will fund operations through the fourth quarter of 2010.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues for the nine months ended September 30, 2009, increased 30% to $6.87 million compared to $5.26 million in the prior year. This was driven by a $6.0 million license fee from Genentech (vs. $3.0 million in 2008) and $667,000 recognized from a new Debiopharm agreement.
- Expense Reduction: Research and development (R&D) expenses decreased 23% to $7.49 million for the nine-month period, primarily due to the licensing of the CUDC-305 program to Debiopharm in August 2009, which shifted future costs to the licensee.
- Cash Flow Improvement: Net cash used in operating activities improved significantly to $4.46 million for the nine months ended September 30, 2009, compared to $11.19 million in the prior year, reflecting lower net losses and changes in working capital.
- Deferred Revenue: Current liabilities increased due to $1.46 million in deferred revenue recorded from the Debiopharm upfront payment, which is being recognized ratably over six months.
Guidance, Outlook, and Risks
Outlook and Guidance:
- The company expects to incur substantial operating losses for the foreseeable future and does not expect to achieve profitability.
- Liquidity beyond late 2010 depends on near-term milestone payments from Debiopharm (expected early 2010) and potential future payments from Genentech.
- Key drivers include the progress of Genentech's pivotal Phase II trial for GDC-0449 in basal cell carcinoma and the initiation of Phase I trials for Debio 0932 by Debiopharm.
Management Commentary:
- Genentech's GDC-0449 showed encouraging Phase I data with a 55% response rate in advanced basal cell carcinoma patients.
- Curis is advancing its internal candidate CUDC-101 (targeting HDAC, EGFR, and Her2) in a Phase I trial, with dose escalation expected to complete in late 2009 or early 2010.
Risks and Contingencies:
- Financing Risk: The company requires substantial additional capital to continue operations. Failure to secure funding could force the curtailment of development programs.
- Collaboration Dependence: Success is heavily reliant on Genentech and Debiopharm to advance drug candidates; these partners have discretion over development efforts and may terminate agreements.
- Regulatory Risk: All drug candidates are in early stages; clinical trials may fail, or regulatory approvals may be delayed or denied.
- Stock Price: The company faces potential delisting from NASDAQ if the stock price remains below $1.00 for 30 consecutive business days.
Investor Verification Checklist
- Cash Runway: Verify if the $27.2 million in liquid assets is sufficient to fund the Phase I trial of CUDC-101 and general operations through Q4 2010 without additional financing.
- Debiopharm Milestones: Monitor the timeline for Debiopharm's Clinical Trial Application (CTA) filing and the treatment of the fifth patient, which trigger contingent payments.
- Genentech Trial Data: Track the results of the pivotal Phase II trial for GDC-0449 in basal cell carcinoma, as this is a primary revenue driver.
- Stock Listing Status: Confirm the current trading price relative to the $1.00 NASDAQ minimum bid price requirement to assess delisting risk.
- Revenue Recognition: Review the accounting treatment of the Debiopharm upfront fee, specifically the six-month recognition period and the classification of deferred revenue.